Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY003-207 in Healthy Participants

NCT06873724 is registered in ClinicalTrials.gov with Spyre Therapeutics, Inc. as lead sponsor.

NCT NCT06873724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06873724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY003-207 in Healthy Participants
Lead sponsor
Spyre Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 10, 2025
Completion date
November 18, 2026
Enrollment
59 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy